JP7318889B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP7318889B2
JP7318889B2 JP2019559413A JP2019559413A JP7318889B2 JP 7318889 B2 JP7318889 B2 JP 7318889B2 JP 2019559413 A JP2019559413 A JP 2019559413A JP 2019559413 A JP2019559413 A JP 2019559413A JP 7318889 B2 JP7318889 B2 JP 7318889B2
Authority
JP
Japan
Prior art keywords
alkyl
trifluoromethyl
pyrido
methyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019559413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505454A (ja
JP2020505454A5 (enExample
Inventor
エー． ワード、ステファン
ジェイ． テイラー，マーク
エム． オネイル，ポール
デイヴィッド ホン，ウェイチィァン
ベナユード，ファリッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2020505454A publication Critical patent/JP2020505454A/ja
Publication of JP2020505454A5 publication Critical patent/JP2020505454A5/ja
Priority to JP2023004747A priority Critical patent/JP2023052427A/ja
Application granted granted Critical
Publication of JP7318889B2 publication Critical patent/JP7318889B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019559413A 2017-01-17 2018-01-17 化合物 Active JP7318889B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023004747A JP2023052427A (ja) 2017-01-17 2023-01-16 化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1700814.5A GB201700814D0 (en) 2017-01-17 2017-01-17 Compounds
GB1700814.5 2017-01-17
PCT/IB2018/000216 WO2018134685A2 (en) 2017-01-17 2018-01-17 Compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023004747A Division JP2023052427A (ja) 2017-01-17 2023-01-16 化合物

Publications (3)

Publication Number Publication Date
JP2020505454A JP2020505454A (ja) 2020-02-20
JP2020505454A5 JP2020505454A5 (enExample) 2021-03-11
JP7318889B2 true JP7318889B2 (ja) 2023-08-01

Family

ID=58463323

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019559413A Active JP7318889B2 (ja) 2017-01-17 2018-01-17 化合物
JP2023004747A Withdrawn JP2023052427A (ja) 2017-01-17 2023-01-16 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023004747A Withdrawn JP2023052427A (ja) 2017-01-17 2023-01-16 化合物

Country Status (5)

Country Link
US (2) US11518760B2 (enExample)
EP (1) EP3571204A2 (enExample)
JP (2) JP7318889B2 (enExample)
GB (1) GB201700814D0 (enExample)
WO (1) WO2018134685A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
BR112020026681A2 (pt) 2018-06-27 2021-04-06 Bristol-Myers Squibb Company Compostos naftiridinona substituídos úteis como ativadores de célula t
ES2950007T3 (es) 2018-06-27 2023-10-04 Bristol Myers Squibb Co Compuestos de naftiridinona útiles como activadores de células T
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
CN109651171A (zh) * 2019-01-13 2019-04-19 苏州鹏旭医药科技有限公司 依拉戈利及其钠盐的中间体及其盐的制备方法和应用
MX2021009667A (es) 2019-02-13 2021-12-10 Ptc Therapeutics Inc Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
US12398140B2 (en) 2019-02-13 2025-08-26 Ptc Therapeutics, Inc. Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
US20230148450A9 (en) * 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
KR20220016074A (ko) * 2019-05-31 2022-02-08 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CA3160053A1 (en) * 2019-12-12 2021-06-17 Ptc Therapeutics, Inc. Compounds for treating familial dysautonomia
BR112022012222A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Derivados de piperazina substituídos úteis como ativadores de células t
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
WO2022058896A1 (en) * 2020-09-15 2022-03-24 Cadila Healthcare Limited Inhibitors of low molecular weight protein tyrosine phosphatase for management of metabolic disorder
EP4214204A1 (en) 2020-09-18 2023-07-26 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
GB202100635D0 (en) 2021-01-18 2021-03-03 Liverpool School Tropical Medicine Compounds and methods for treating or preventing dirofilaria infection in a mammal
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022187411A1 (en) 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
KR20250004810A (ko) 2022-04-20 2025-01-08 컴쿼트 바이오사이언시즈 인크. 대환식 헤테로환 및 이의 용도
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors
CN118084873A (zh) * 2022-11-28 2024-05-28 上海美悦生物科技发展有限公司 螺杂环取代的嘧啶类化合物及其制备方法和用途
WO2025012643A1 (en) * 2023-07-11 2025-01-16 Tay Therapeutics Limited Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents
WO2025147603A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Thienopyridine compounds and uses thereof
CN119161336B (zh) * 2024-07-24 2025-09-05 四川大学 一种作为Blimp1抑制剂的小分子化合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
JP2007513996A (ja) 2003-12-16 2007-05-31 ファイザー・プロダクツ・インク ＰＤＥ２インヒビターとしてのピリド［２，３−ｄ］ピリミジン−２，４−ジアミン類
WO2009001060A2 (en) 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
JP2013500255A (ja) 2009-07-21 2013-01-07 プレジデント アンド フェロウズ オブ ハーバード カレッジ 自食作用の強力な小分子阻害剤、およびそれの使用方法
CN106083742A (zh) 2016-05-31 2016-11-09 广东工业大学 一种2,4‑二胺基喹唑啉衍生物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
AU2879799A (en) * 1998-02-26 1999-09-15 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
AU2002364211A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2010042489A2 (en) * 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
FR2959510B1 (fr) 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
WO2012097258A2 (en) * 2011-01-15 2012-07-19 The Regents Of The University Of California Formulations for the prevention and treatment of wolbachia-related disease
CN103087077B (zh) * 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
CN103204816B (zh) * 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
KR102394917B1 (ko) 2015-03-04 2022-05-09 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
JP2007513996A (ja) 2003-12-16 2007-05-31 ファイザー・プロダクツ・インク ＰＤＥ２インヒビターとしてのピリド［２，３−ｄ］ピリミジン−２，４−ジアミン類
WO2009001060A2 (en) 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
JP2013500255A (ja) 2009-07-21 2013-01-07 プレジデント アンド フェロウズ オブ ハーバード カレッジ 自食作用の強力な小分子阻害剤、およびそれの使用方法
CN106083742A (zh) 2016-05-31 2016-11-09 广东工业大学 一种2,4‑二胺基喹唑啉衍生物及其制备方法和应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAKRABORTI A K，3D-QSAR STUDIES ON THIENO[3,2-D]PYRIMIDINES AS PHOSPHODIESTERASE IV INHIBITORS，BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS，NL，PERGAMON，2003年，VOL:13, NR:8,，PAGE(S):1403 - 1408，http://dx.doi.org/10.1016/S0960-894X(03)00172-0
DIEGO GONZALEZ CABRERA，2,4-DIAMINOTHIENOPYRIMIDINES AS ORALLY ACTIVE ANTIMALARIAL AGENTS，JOURNAL OF MEDICINAL CHEMISTRY，2014年01月28日，VOL:57, NR:3,，PAGE(S):1014 - 1022，http://dx.doi.org/10.1021/jm401760c
DIEGO GONZALEZ CABRERA，STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF ORALLY ACTIVE ANTIMALARIAL 2,4-DIAMINO-THIENOPYRIMIDINES，JOURNAL OF MEDICINAL CHEMISTRY，2015年09月08日，VOL:58, NR:18,，PAGE(S):7572 - 7579，http://dx.doi.org/10.1021/acs.jmedchem.5b01156
MARIA FONT，NEW INSIGHTS INTO THE STRUCTURAL REQUIREMENTS FOR PRO-APOPTOTIC AGENTS BASED ON 2,4-以下備考，EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY，フランス，2011年05月24日，VOL:46, NR:9,，PAGE(S):3887 - 3899，http://dx.doi.org/10.1016/j.ejmech.2011.05.060，DIAMINOQUINAZOLINE, 2,4-DIAMINOPYRIDO[2,3-D]PYRIMIDINE AND 2,4-DIAMINOPYRIMIDINE DERIVATIVES
ODINGO JOSHUA，SYNTHESIS AND EVALUATION OF THE 2,4-DIAMINOQUINAZOLINE SERIES AS ANTI-TUBERCULAR AGENTS，BIOORGANIC & MEDICINAL CHEMISTRY，英国，PERGAMON，2014年10月22日，VOL:22, NR:24,，PAGE(S):6965 - 6979，http://dx.doi.org/10.1016/j.bmc.2014.10.007

Also Published As

Publication number Publication date
JP2020505454A (ja) 2020-02-20
JP2023052427A (ja) 2023-04-11
US20230348460A1 (en) 2023-11-02
WO2018134685A2 (en) 2018-07-26
WO2018134685A3 (en) 2018-11-15
US11518760B2 (en) 2022-12-06
EP3571204A2 (en) 2019-11-27
US20190345157A1 (en) 2019-11-14
GB201700814D0 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
JP7318889B2 (ja) 化合物
AU2021245168B2 (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
US10385051B2 (en) Inhibitors of lysine specific demethylase-1
US10323037B2 (en) Aminopyridazinone compounds as protein kinase inhibitors
US9290507B2 (en) B-RAF kinase inhibitors
US9382241B2 (en) Aminoquinazoline and pyridopyrimidine derivatives
AU2019407650B2 (en) Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
US7041666B2 (en) Adenosine A2a receptor antagonists
US8865703B2 (en) Pyridyltriazoles
CN111212839A (zh) 吡唑并嘧啶酮化合物及其用途
TWI538913B (zh) 嘌呤衍生物
US20120088753A1 (en) Pyrrolopyrimidines and used as kinase inhibitors
TW201738246A (zh) 作為ｔａｍ抑制劑之吡咯并三嗪化合物
TW200835481A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
JP2012507512A (ja) アミロイドβのモジュレーター
US20160045505A1 (en) Compounds and compositions for the treatment of parasitic diseases
CN106243088A (zh) 取代的哌嗪化合物及其使用方法和用途
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
JP6827621B2 (ja) Ｓｕｖ３９ｈ２を阻害するための二環式化合物およびその使用
JP2018531244A6 (ja) Ｓｕｖ３９ｈ２を阻害するための二環式化合物およびその使用
TWI894448B (zh) Ctla-4小分子降解劑及其應用
KR20250002409A (ko) Hpk1 억제제로서의 피리도[3,2-d]피리미딘
US20210221820A1 (en) Compounds for the modulation of myc activity
US20250059188A1 (en) Arylsulphonamide compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230116

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230116

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230126

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230306

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230711

R150 Certificate of patent or registration of utility model

Ref document number: 7318889

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150